Purpose
Purpose (Purpose)
Stasis Solution
FDA Label NDC 10129-031
6 label sections · Submitted to the FDA by Gingi-pak A Division Of The Belport · Indications, Dosage, Usage, and Precautions
Structured Product Label
The following Structured Product Label (SPL) was submitted to the FDA by Gingi-pak A Division Of The Belport for the product Stasis (NDC 10129-031). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient, purpose, uses, directions, warning, keep out of reach of children, stop use and ask a doctor, precautions, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Label Section Quick Index
Uses
Uses (Uses)
Directions
Directions (Directions)
Warning
Warnings (Warning)
Precautions
Precautions Temporary discoloration of tissue may occur for 24 to 48 hours. (Reassure patient that discoloration will disappear).
IT IS NOT RECOMMENDED THAT FERRIC SULFATE SOLUTIONS SUCH AS STASIS BE USED IN COMBINATION WITH EPINEPHRINE OR EPINEPHRINE IMPREGNATED RETRACTION MATERIALS BECAUSE LONG TERM AND POSSIBLE PERMANENT STAINING MIGHT OCCUR.
Stains on hands and clothing may generally be removed with the use of 3% Hydrogen Peroxide.
Storage
Storage (Storage)
* Please review the disclaimer below.
